Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk

A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop b…

In breve

<article class="story default clearfix">

<h2> <a href="https://www.middleeasteye.net/news/irans-world-cup-squad-granted-us-visas-some-staff-blocked" rel="bookmark"> <span class="field field-title">Iran's World Cup squad granted US visas but some staff blocked</spa

Contesto

Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help prevent breast cancer. According to the collected source material from www.sciencedaily.com, A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help prevent breast cancer. Editorial classification signals include category: cronaca ; entities…

Lettura DEO

Verdetto: publish
Confidenza: 82/100

Deterministic fallback judge output. Libre judge fallback via DeepSeek Gamma.

Categoria: cronaca
Entità: Ozempic